


**Think SOY!**

# Bioavailability and Biological Effects of Soy Isoflavones



# Health benefits from soy isoflavones



Epidemiological studies indicate that dietary isoflavones provide health benefits for men and women.



# What are isoflavones ?

- Bioactive **plant chemicals** in dietary sources, have structure **similar to endogenous estrogen**
- Important **non-hormonal properties** (antioxidant, Protease Inhibitor, protein synthesis, etc.)
- Three major families, **Genistein**, **Daidzein**, **Glycitein** in 4 possible forms
  - Aglycone
  - $\beta$ -glucoside
  - malonylglucoside
  - acetylglucoside

Estrogen




Daidzein - aglycone

# What are isoflavones ?


## Phytoestrogen

- Can bind to the mammalian **estrogen receptor** (ER), affinities to ER ranges from  **$10^{-2}$  to  $2 \times 10^{-5}$**  compared to  $17\beta$ -estradiol (human estrogen)
- Have **estrogenic** and/or **anti-estrogenic** effects depending on hormonal environment in the body
- Their **precursors in foodstuffs** might be converted into actual hormones in the human intestinal tract.
- Three main classes:
  - **isoflavones**
  - coumestans
  - lignins

Estrogen



Isoflavone



# Isoflavones in Dietary Sources



- Found in fruit, legumes, whole grains, nuts, etc.
- The legumes, **soy**, has the most concentrated amount
- Typically occur as **glycosides** in raw soybeans and non-fermented soy foods
- In the range of **0.1-3.0 mg/gram** (as is) in soy foods
- Concentrations depend on
  - soybean cultivar
  - environmental conditions
  - the processing procedures

# Physical & chemical properties of isoflavones

- **Stability**

- Aglycones are stable under physiological conditions
- The acetyl- and malonyl-glucose ester bonds are labile at elevated temperatures and under acidic or basic conditions.

- **Solubility**

- The aqueous solubility of aglycones are low and are pH dependent due to the phenolic groups.
- Conjugation to glucose residues increase the solubility, while acetylation or malonylation of the aglycones reduces solubility

# Isoflavone biological activity

- **Bioavailability Studies**

- Tissue distribution study

- Pharmacokinetics after a single challenge

- Impact of isoflavone structure

- **Mechanism**

- Postulated metabolism pathway

- A cellular transport model

- **Biological Effects**

- hormonal effects

- cancer modification

# Bioavailability - (Yueh & Chu, 1977)

## Tissue Distribution Studies

- Study Design

Rats 15 mins after intravenous injection of 40mg of daidzein / B.W.

- Results

- **High** in plasma, liver, lung, kidney (30 $\mu$ g/g, w.w.)
- **Modest** in skeletal muscle, spleen and heart (15-20  $\mu$ g/g w.w.)
- **Low** in brain and testis (2-5  $\mu$ g/g w.w.)

## **Bioavailability - Pharmacokinetic studies (King and Bursill, 1998)**

### **Plasma and urinary kinetics after a single challenge**

#### **Study Design\_\_\_\_**

- **6 healthy men (ave. 37y)**
- **soy-free diet for 1 wk**
- **Two phases**

**Phase 1: To determine the time required to reach Max. plasma concentration**

**Phase 2: To determine the elimination half-life**

## **Bioavailability - Pharmacokinetic studies (King and Bursill, 1998)**

### **Plasma and urinary kinetics after a single challenge**

**Phase 1: To determine the time required to reach Max. plasma concentration**

- **Soy flour meal (0.84g/kg body wt)  
~ 2.7 $\mu$ mol daidzein, 3.6  $\mu$ mol genistein /kg body wt**
- **10ml blood sample before and 1,2,4,6 and 8h after the meal**

**Observations:**

- **Isoflavone began to appear in plasma within 30min after consumption**
- **Isoflavone concns rose slowly and reached max. values of ~ 3.14  $\mu$ mol/L at ~7h for daidzein and ~4mol/L at ~ 8h for genistein.**

## Bioavailability - Pharmacokinetic studies (King and Bursill, 1998)

### Plasma and urinary kinetics after a single challenge

Phase 2: To determine the elimination half-life

- Urine samples collected 24h before and over the periods 0-11, 11-12, 12-14, 14-16, 16-18, and 18-35h after the meal
- Plasma collected 11,12,14,16,18 and 35h after the meal

Observations:

- Elimination half-lives: **5-9 hrs**, returning to baseline by about 48 hrs after a meal
- Excreted in the urine as **glucuronides** and **sulphates**.
- Much **greater excretion** of **daidzein** than genistein (mean recoveries of ~ 62% and ~ 22% of the dose)
- A **wide range** of the percentage of ingested dose that is excreted by urine, however, the extent to which genistein is absorbed following ingestion is about the same or somewhat more than daidzein

## Bioavailability - Pharmacokinetic studies (King and Bursill, 1998)

### Plasma and urinary kinetics after a single challenge

#### Conclusions

- Higher **urinary** excretion of daidzein compared with genistein suggests a greater fractional excretion of the latter via the **bile**.
- Interindividual differences may reflect differences in gut microflora populations
- The nature of soy food may influence bioavailability through differences in the nature of isoflavone conjugates
- The **difference in conjugation pattern** may influence the ease of hydrolysis of the glycosidic bond or bacterial degradation, and hence, **bioavailability**.

# Bioavailability - Aglycone or glucosides ?

## A human study vs. an animal study

(Hutchins A M, et al., 1995)

### Study Design\_

- 17 **male** consuming either:
  - (F) 112g of fermented soy tempeh, or
  - (UF) 125g of unfermented soybean
- for nine days

### Observation\_

Urinary recovery of daidzein and genistein:

(F) 9.7% and 1.9%  
(UF) 5.7% and 1.3%

### Suggesting:

**Isoflavone aglycones may be more bioavailable than their glucosides.**

(King et al., 1996)

### Study Design\_

**Rats** were given a single dose of

- (G) genistein (20mg/kg b.d.), or
- (C) an equivalent dose of its conjugated forms in soy extract

Observations on plasma, urinary and fecal excretion at 2h, 8h, and 48h after dosing.

### Suggesting:

**The extent of absorption of genistein is similar for the aglycone and conjugated forms.**

**Although higher initial plasma concn. May be achieved with the aglycone, by 8h the concentrations are similar.**



## Bioavailability – (Franke et al, 1998)

### Isoflavones in human breast milk and other biological fluids

#### Study Design\_\_\_\_


- single challenge with 20g roasted soybeans (37mg isoflavones)
- detect isoflavones in plasma, breast milk, and urine

#### Observations\_\_\_\_

- mean total isoflavones:
  - 2.0  $\mu\text{mol/L}$  in plasma
  - 0.2  $\mu\text{mol/L}$  in breast milk
  - 3.0  $\mu\text{mol/L}$  in urine


# Possible Metabolic Pathway

Conjugation and Deconjugation — the major route of metabolism



# Possible Metabolic Pathway

## A Cellular Intestinal Transport Model on Caco-2 cells




- Isoflavone aglycones are more rapidly transported than the glucoside

- The aglycone **probably** enter the cells by passive diffusion, but the mechanism of uptake of isoflavone glucosides has not been established clearly.

# Possible Metabolic Pathway

## Conjugation — the major route of metabolism



# Possible Metabolic Pathway

## Unknown/Unclear

Transport mechanism thru intestinal cell wall, passive diffusion, facilitated transport, or active transport ?

Whether glycosides can be absorbed as is?

Whether conjugation (e.g. glucuronidation) take places exclusively in the liver, or in the intestine ?

# Bioavailability

## HOT TOPICS —Soy- based Infant formula

Subject: Soy-based milk replacers to the newborn

- **Concerns:**
  - isoflavone supply may **amount** to 3mg/kg b.m.(exceed the amount needed to alter reproductive hormones in adults
  - the glucuronidation potency of **infant liver** is not fully developed, may lead to higher bioavailability of isoflavoe
- **On the other hand:**
  - phytoestrogens are discussed as having **positive effects** on newborns (e.g. Improved resistance against some chronic diseases in adulthood)
  - **no adverse** clinical effects have been observed in infant fed with soy products.

## Biological effects - Case Study III (Cassidy and Bingham, 1995)

### Biological effects in young women


#### Study Design \_\_\_\_\_

- 15 healthy **premenopausal women**
- 4-6 month in **controlled metabolic** suites)
- **Hormonal status** measured over menstrual cycles
- **60g/day soy protein** (**45mg/day Isolfavone** in different conjugated forms)
- Similar non-soy diet as control

- **Diet modified hormonal status in normal ovulating women.**
- **Dietary composition of isoflavones is probably responsible for the observed biological effects.**
- **Inconjugated isoflavones are potentially more efficient probably due to their amphiphilic properties**
- **Reduction in total cholestroal levels and a trend towards ↓ in LDL: HDL value**

# Soy isoflavones and cancer

## Breast Cancer Mortality vs. Soy Consumption



# **Soy isoflavones and cancer – a review**

(Boersma et al., 2001)

**Purified isoflavones shown in vitro to suppress a wide variety of cancer cell lines.**

**Proposed mechanisms include**

- regulation of estrogen-mediated events
- inhibition of tyrosine kinase and DNA topoisomerase activities
- synthesis and release of TGF $\beta$
- modulation of apoptosis
- interaction with oxidants produced by inflammatory cells

**However\_\_**

**Biological effects in cell culture occur far above the physiological concentrations.**


# Future studies

---

- **Biotransformation study**
- **Identification of isoflavone metabolites**
- **Dose-response study**
- **Antioxidant effects in oxidation events**
- **Possible synergism between soy isoflavones and other soy components on cancer cell growth inhibition**

# Biotransformation

## Isoflavones and their precursors in soy foods



# Relatives to isoflavones

## Coumestans

- Structurally and biosynthetically related to the isoflavones
- Occur in legume shoots and sprouts
- Estrogenic activity greater than isoflavones (affinity to ER is ~10% of 17 $\beta$ -estradiol)
- Mainly act as an estrogen agonist
- Stimulate bone-mineralizing activity in animal model

# Relatives to isoflavones

## Lignans

- Contain a diphenolic ring system and are stereoisomeric
- Two major mammalian lignans, **enterodiol** and **enterolactone**
  - The products of colonic bacterial metabolism of the plant lignans secoisolariciresinol and matairesinol
- Weak estrogenic, some have antioxidative properties
- Dietary sources are flax seed, whole grain products, fruits, vegetables, tea.
- Conc'n. in human can exceed the endogenous conc'n.s of steroid hormones up to 1000 times.
- Consumption has been negatively correlated with coronary heart disease.
- Inhibit steroid hormones metabolizing enzymes
- Ingestion of flax seed revealed a cancer preventive roles at early tumor stages in animal models
- Enterolactone can stimulate growth of breast cancer cell lines.

# Relatives to isoflavones

## Phytosterols



- Daily intake estimated to be 160-360mg/day in Western diets
- Most important phytosterols in nature are  $\beta$ -sitosterol, campesterol, stigmasterol and dihydrobrassicasterol
- Natural constituents of foodstuffs (Bourbon whisky contain  $\beta$ -sitosterol in addition to biochanin A)
- Weak estrogenic
- Seems to reduce steroid biosynthetic capacity through effects on cholesterol availability or the activity of the side-chain cleavage enzyme cytochrome P450
- Reduce plasma total and LDL cholesterol levels (may due to reduced intestinal absorption of cholesterol)